Advertisement
Screener

Caribou Biosciences, Inc. (CRBU) Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

2.8 / 5 stars · 68/120 Roast Me

Caribou Biosciences, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

Caribou Biosciences, Inc. (CRBU) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $6.64 million as of 2025-12-31, per its 10-K filed 2026-03-05.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-05

  • 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.64M.
  • 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.98M.
  • 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.63M.
  • 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.92M.
Period endDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
2025-12-31$6.64M
10-K · filed 2026-03-05
2024-12-31$5.98M
10-K · filed 2026-03-05
2023-12-31$4.63M
10-K · filed 2025-03-10
2022-12-31$2.92M
10-K · filed 2024-03-11
2021-12-31$576.00K
10-K · filed 2023-03-09
2020-12-31$203.00K
10-K · filed 2022-03-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22